Internal Medicine

A younger baseline age and more injections during the first year of treatment was linked to better long-term outcomes.

Venetoclax in combination with azacitidine was shown to prolong survival and increase chance of remission.

In data presented at UEG, investigators find post-dupilumab transcriptome closely resembles the transcriptome of a healthy control group.

New data shows that clinical isolates of C. difficile are variably affected by manuka honey in terms of growth inhibition and bactericidal activity.

Many patients do not see meaningful improvement with the current standard treatment. New data suggest this monoclonal antibody might be a better choice.

The quadrivalent, virus-like particle influenza vaccine has potential to offer substantial protection in adults.

The longitudinal study included 209 children, one of the largest samples in the world for a study on this topic.

The first-in-class drug in severe asthma significantly reduced the exacerbation rate by 35% compared with placebo.

The study observed 50 women taking infliximab, adalimumab, and vedolizumab.

The drug has potential to be best-in-class treatment option for children aged 6-11 years with uncontrolled moderate-to-severe asthma.

NASH and NAFLD are notoriously difficult to treat conditions.

An expert offers 5 tips to physicians and patients on best practices for managing symptoms related to allergic asthma.

The schizophrenia drug currently has a PDUFA date set for November 15.

The Arbor Pharmaceutical drug is aimed at treating ADHD without being manipulated for non-oral use.

About 69% of patients with CIU were either obese or overweight, and experienced a longer duration of disease than those who had lower weight values.

TLR9 activation shows potential as a target for ulcerative colitis and warrants further testing.

The investigators also found the effects of dapagliflozin were similar in patients with type 2 diabetes and those without type 2 diabetes.

There was also a decline depression care in recent years among adolescents and young adults.

Although sickle cell disease is the most common inherited blood disorder in the US, there are still knowledge and prioritization gaps that need to be addressed.

New research suggests the Janus kinase 1 and 2 inhibitor relieves symptoms of atopic dermatitis at a daily dose of 4 mg.

Cytokinetics announces presentations on two trials assessing omecamtiv mecarbil in patients with heart failure and reduced ejection fraction.

The Digihaler is a digital inhaler aimed at improving inhaler techniques.

These findings underline the importance of aggressive management to treat IBD and ACS comorbidities to improve outcomes.

Dr. Fauci gives perspective on the future presence of the virus, improving US pandemic preparedness, and the theological divisions which have plagued national response.

Patients who received the combination of nivolumab and ipilimumab survived a median of 18.1 months, while patients who underwent chemotherapy survived a median of 14.1 months.